Oncocross (382150) Fundamentals 2026 — Revenue Analysis | SniperIQ
Oncocross (382150) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩37.4B, trading at ₩3065.00 on the KOE. This SniperIQ fundamentals page covers Oncocross's valuation, profitability (net margin -1959.1%), revenue (₩370M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Oncocross's market cap?
Oncocross (382150) has a market capitalization of approximately ₩37.4B, trading at ₩3065.00 on the KOE. Market cap moves with the live share price.
What is Oncocross's P/E ratio?
Oncocross's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Oncocross?
Oncocross runs a net profit margin of -1959.1%, a gross margin of -232.6%, and an operating margin of -1885.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Oncocross generate?
Oncocross reported revenue of ₩370M for fiscal year 2025, with net income of -₩8.9B and earnings per share (EPS) of -746.83. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Oncocross pay a dividend?
Oncocross does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Oncocross financially healthy?
Oncocross carries a debt-to-equity ratio of 0.72x and a current ratio of 3.75x, with a market beta of -0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Oncocross a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Oncocross (382150) the key facts are: market cap ₩37.4B, revenue ₩370M, 52-week range 2920-14490. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Oncocross's full fundamentals live
Get Oncocross's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.